| 查看: 136 | 回复: 0 | |||
| 当前主题已经存档。 | |||
[交流]
Sanofi Obesity Drug Gets Final Okay From UK's NICE
|
|||
|
LONDON (Reuters) Jun 25 - Sanofi-Aventis won a final green light for its obesity drug Acomplia (rimonabant) from Britain's cost-effectiveness watchdog NICE on Wednesday, clearing the way for doctors to prescribe it on the state health service. The move was expected following a positive appraisal from the National Institute for Health and Clinical Excellence (NICE) in March. It marks a small positive for the French drugmaker's once much-hyped medicine, which has failed to live up to early expectations. NICE's final guidance recommends using Acomplia as an addition to diet and exercise for obese or overweight adults who don't respond to or are intolerant of two other weight-loss drugs, orlistat and sibutramine. But NICE cautioned that treatment should not continue beyond 6 months unless patients lost at least 5 percent of their initial body weight and there should, in any event, be a formal clinical assessment after 2 years. The UK decision contrasts with Germany where Acomplia is not reimbursed by health insurers because it is deemed simply to improve lifestyle. Acomplia was once touted as a multibillion-dollar seller, but hopes for the product dimmed last year when a U.S. expert panel recommended against its approval in the world's biggest market, after it was linked to rare cases of suicidal thoughts. Sanofi said in October it expected only limited sales of the drug in the next few years, until new clinical trial results testing it in diabetes are ready for submission to regulators in 2009. Worldwide sales of the drug were a meagre 79 million euros ($122.9 million) last year. Roche makes the older weight-loss drug orlistat under the brand name Xenical, while sibutramine is marketed by Abbott Laboratories under the brand names Meridia or Reductil. |
回复此楼» 猜你喜欢
澳门理工大学人工智能药物发现中心招收2026级博士研究生（申请-考核制）
已经有10人回复
-
药学专硕申博
已经有18人回复
-
药物学论文润色/翻译怎么收费?
已经有230人回复
-
可能上不了岸？有条件的可以考虑其他出路
已经有0人回复
-
分子对接相关经验分享
已经有0人回复
-
分子对接相关经验分享
已经有0人回复
-
使用MolAICal生成小分子CHARMM力场拓扑和参数文件
已经有0人回复
-
这个自发加氧反应的机理是什么？
已经有7人回复
-
2026生物医药产业发展大会
已经有0人回复
-
国青中了
已经有21人回复
投票:
10